It's not all that unusual for analysts and investors to accentuate the negative when it comes to Big Pharma, and Roche (RHHBY.PK) is no exception. Although this company has a pretty clean patent cliff over the next few years, leading positions in lucrative markets and solid upcoming pipeline products, more attention has gone to some pipeline setbacks and a big R&D restructuring. Although Roche may no longer be the most compelling European pharmaceutical, it's still a quality name worth considering on dips and pullbacks.
Please read more here:
Roche Building On Its Strengths